Capital One National Association cut its stake in Pfizer Inc. (NYSE:PFE) by 3.0% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 396,457 shares of the biopharmaceutical company’s stock after selling 12,440 shares during the period. Pfizer comprises about 1.1% of Capital One National Association’s holdings, making the stock its 13th largest position. Capital One National Association’s holdings in Pfizer were worth $13,959,000 as of its most recent SEC filing.
A number of other hedge funds also recently made changes to their positions in the company. Catamount Wealth Management boosted its stake in shares of Pfizer by 14.2% in the first quarter. Catamount Wealth Management now owns 4,395 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 545 shares during the last quarter. Stuart Chaussee & Associates Inc. boosted its stake in shares of Pfizer by 64.3% in the second quarter. Stuart Chaussee & Associates Inc. now owns 5,430 shares of the biopharmaceutical company’s stock valued at $193,000 after buying an additional 2,125 shares during the last quarter. Oakmont Partners LLC bought a new stake in shares of Pfizer during the second quarter valued at approximately $211,000. Financial Strategy Network LLC bought a new stake in shares of Pfizer during the first quarter valued at approximately $205,000. Finally, Moon Capital Management LLC bought a new stake in shares of Pfizer during the second quarter valued at approximately $237,000. Institutional investors and hedge funds own 69.65% of the company’s stock.
Pfizer Inc. (NYSE:PFE) traded down 0.27% on Friday, hitting $33.56. 14,819,706 shares of the company’s stock were exchanged. The company has a market cap of $203.56 billion, a PE ratio of 29.75 and a beta of 0.86. Pfizer Inc. has a 12-month low of $28.25 and a 12-month high of $37.39. The company’s 50-day moving average price is $34.29 and its 200-day moving average price is $34.19.
Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.62 by $0.02. The business had revenue of $13.10 billion for the quarter, compared to the consensus estimate of $13.01 billion. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The business’s revenue was up 10.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.56 EPS. Analysts forecast that Pfizer Inc. will post $2.46 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Friday, November 11th will be paid a $0.30 dividend. This represents a $1.20 dividend on an annualized basis and a dividend yield of 3.58%. The ex-dividend date is Tuesday, November 8th. Pfizer’s dividend payout ratio (DPR) is 95.24%.
Several analysts have recently issued reports on PFE shares. Argus restated a “buy” rating and set a $39.00 target price on shares of Pfizer in a research report on Sunday, August 28th. Vetr upgraded shares of Pfizer from a “buy” rating to a “strong-buy” rating and set a $37.94 target price on the stock in a research report on Monday, June 27th. Deutsche Bank AG restated a “buy” rating on shares of Pfizer in a research report on Wednesday, June 15th. Barclays PLC restated an “equal weight” rating and set a $34.00 target price on shares of Pfizer in a research report on Tuesday, August 2nd. Finally, Jefferies Group decreased their target price on shares of Pfizer from $42.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, June 20th. Ten investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $38.78.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.